Molecular response, the determination of BCR‐ABL transcripts over time, is a parameter used to determine whether CML is in remission or is persisting after TKIs treatment, and it has been proposed as an indicator to stop treatment. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.